Recent Updates
Recently added Catalysts
Trending News :
The freshest biotech headlines moving stocks right now, newest first.
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
RLMD ▲ 7.26%
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
CMPS ▼ 27.31%
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
INO ▲ 213.75%
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
BSX ▲ 5.57%
Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations
TRLV ▲ 7.98%Eikon Therapeutics to Participate in Multiple Investor Conferences in November
EIKN ▲ 6.97%
Upcoming Catalysts That Could Move the Market
REC-4881 is currently an investigational oral drug undergoing a Phase 1b/2… (Read More)
AX-0811 is ProQR Therapeutics' next-generation RNA-editing oligonucleotide aimed… (Read More)
DA-1726 is a once-weekly subcutaneous dual oxyntomodulin analogue developed by… (Read More)
PAS-004 is an investigational oral macrocyclic MEK1/2 inhibitor being developed… (Read More)
Atebimetinib is an investigational oral MEK-pathway inhibitor developed by… (Read More)
The available public evidence supports a preliminary probability of approval… (Read More)
Belapectin, developed by Galectin Therapeutics, is a carbohydrate-based… (Read More)
The investigational drug [212Pb]Bamzireotide Navoxetan, also known as VMT-α-NET… (Read More)
COMP360 is Compass Pathways’ proprietary synthetic psilocybin formulation under… (Read More)
Volixibat is an oral ileal bile acid transporter (IBAT) inhibitor developed by… (Read More)
Vutrisiran, marketed as AMVUTTRA, is Alnylam Pharmaceuticals’ innovative… (Read More)
Latest Stocks News :
ADCTADC Therapeutics to Present at November Investor Conferences
ADC Therapeutics will present at the Guggenheim and Jefferies investor conferences in November 2026. CEO Ameet Mallik is scheduled to speak at both events, highlighting the company's advancements in antibody drug conjugates. Live webcasts will be available for investors, with replays accessible for 30 days post-event.
Read more →
KLRAKailera Therapeutics to Participate in November Investor Conferences
Kailera Therapeutics announced participation in several upcoming investor conferences, including the Stifel 2026 Healthcare Conference and Jefferies Global Healthcare Conference. The company is focused on obesity care, advancing multiple clinical-stage candidates, including ribupatide injection, which is in Phase 3 trials. The management team will present at these events to discuss their innovative pipeline.
Read more →
DCOYDecoy Therapeutics Provides Third Quarter 2026 Business Update
Decoy Therapeutics reported progress in its pan-coronavirus program, expecting to file a CTA/IND in the second half of 2027. The optimized candidate may allow for once-weekly dosing, enhancing patient adherence. The company has $8.1 million in cash, supporting its ongoing development efforts.
Read more →
USNAUSANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity
USANA Health Sciences (NYSE: USNA) announced that its BiOmega omega-3 supplement earned the ConsumerLab Seal of Approval for quality and purity. The product passed independent testing for label accuracy and heavy metals. BiOmega is one of seven USANA products currently approved by ConsumerLab.
Read more →
ALKSAlkermes plc Reports Third Quarter 2026 Financial Results
Alkermes plc reported its financial results for the third quarter of 2026. The earnings press release and presentation are available on the company's investor relations website. A conference call and webcast are scheduled for today at 8:00 a.m. ET to discuss these results and provide further updates.
Read more →
CDNACareDx Announces Third KOAR Analysis Published in Transplantation
CareDx announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry in the journal Transplantation. This third manuscript explores the relationship between early post-transplant AlloSure kidney donor-derived cell-free DNA levels and transplant outcomes. The findings aim to enhance understanding of kidney transplant success.
Read more →
RGNXREGENXBIO to Participate in Stifel 2026 Healthcare Conference
REGENXBIO Inc. will participate in the Stifel 2026 Healthcare Conference on November 11, 2026. The event will feature a fireside chat at 9:20 a.m. ET in New York. A live webcast will be available on the company's website, with an archived replay for 30 days.
Read more →
DFTXDefinium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics announced its participation in upcoming investor conferences, including the Stifel 2026 Healthcare Conference. The management team will engage with investors to discuss the company's innovative therapeutics targeting psychiatric and neurological disorders. This involvement aims to strengthen relationships with potential investors.
Read more →
DTILPrecision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences reported its third quarter 2026 results, highlighting the dosing of the first patient in the FUNCTION-DMD study. The company also announced a late-breaking presentation for its PBGENE-HBV trial at the upcoming AASLD meeting. With a cash balance of $108 million, Precision expects to fund operations through 2028.
Read more →
IVVDInvivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. announced the grant of stock options to seven new non-executive employees as an inducement for their employment. The options total 175,000 shares with an exercise price of $0.5817, vesting over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects Invivyd's commitment to attracting talent.
Read more →